


 Cite this: *RSC Adv.*, 2020, 10, 15656

# Introducing chirality in halogenated 3-arylsydnes and their corresponding 1-arylpyrazoles obtained by 1,3-dipolar cycloaddition†

 Marcel Mirel Popa,<sup>a</sup> Sergiu Shova,<sup>b</sup> Madalina Hrubaru,<sup>a</sup> Loredana Barbu,<sup>a</sup> Constantin Draghici,<sup>a</sup> Florea Dumitrascu<sup>ID</sup>\*<sup>a</sup> and Denisa E. Dumitrescu<sup>c</sup>

New 1-arylpyrazoles substituted with halogen atoms (Br, I) were synthesized from the corresponding sydnones by 1,3-dipolar cycloaddition. By introduction of a prochiral group such as isopropyl, in the *ortho* position of the benzene ring, in the starting phenylglycine **1** the rotamers caused by the hindered rotation between the phenyl and the heterocyclic ring were detected by NMR spectroscopy for 1-arylpyrazoles and for the first time for 3-arylsydnes. The *N*-nitrosophenylglycines present *E*–*Z* stereoisomerism due to the partial C–N double bond character. All the new compounds were structurally characterized by NMR spectroscopy and confirmed by X-ray crystallography. The crystal structures of *N*-nitrosophenylglycine **2c** and of the sydnone **3c** present similar Br⋯Br type II halogen contacts.

Received 13th March 2020

Accepted 11th April 2020

DOI: 10.1039/d0ra02368j

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

Mesoionic compounds<sup>1–5</sup> are versatile intermediates in the synthesis of bioactive pyrrole and pyrazole derivatives.<sup>6–11</sup> Sydnones<sup>12,13</sup> in particular, have been employed as 1,3-dipoles in obtaining *N*-arylpyrazoles by 1,3-dipolar cycloaddition reaction.<sup>14–28</sup> *N*-Arylpyrazole derivatives have been shown to possess antithrombotic,<sup>29</sup> anticancer,<sup>30</sup> parathyroid dysfunction,<sup>31</sup> anti-biofilm,<sup>32</sup> and antipain<sup>33</sup> activity which makes them valuable targets for the pharmaceutical field.

Chirality is important in drug-target recognition processes<sup>34</sup> and atropisomerism could be a useful tool for generating chiral drugs<sup>34</sup> by blocking the free rotation about a bond axis through steric factors. The most studied systems are biaryls.<sup>35</sup> The structure of *N*-arylpyrazoles implies the existence of axial chirality when the right substituents are grafted on their framework. By fine tuning of the substituents on the aryl or pyrazole rings the free rotation about the bond axis between the two rings could be hindered and thus leading to the existence of the two rotational isomers. Depending on the value for the

energy of the free rotation about the two rings, the enantiomers can be detected by NMR spectroscopy or even the physical separation of the conformational isomers could be achieved. However, even in the case the free energy of rotation is smaller and the atropisomers are not easily separable in normal conditions but instead rotamers are detectable, the conformational analysis is still an important thing to be investigated under de drug-target interaction paradigm, for example.<sup>36</sup>

Herein we present the synthesis of new halogenated 1-arylpyrazoles bearing in mind that halogen atoms could enhance their bioavailability<sup>37</sup> due to halogen bonding<sup>38</sup> formation with specific nucleophilic sites in proteins. The introduction of axial chirality in the new 1-arylpyrazoles was pursued and investigated during the synthesis steps starting with the *N*-nitrosoderivatives and sydnone intermediates. The structures of the compounds were confirmed by X-ray single crystal diffraction analysis.

## Results and discussions

### Synthesis and characterization of *N*-nitrosophenylglycines **2**

The synthesis of the 3-arylsydnes was achieved from corresponding *N*-nitroso-*N*-(2-isopropylphenyl)glycines obtained according to literature procedures.<sup>16</sup> The starting *N*-arylglycine **1a** (Scheme 1), precursor of the *N*-nitrosoglycines, was obtained from 2-isopropylaniline by condensation with monochloroacetic acid. Compound **1** was further brominated with Br<sub>2</sub> to yield the *N*-arylglycines **1b,c** (Scheme 1).



<sup>a</sup>Center of Organic Chemistry “C. D. Nenitzescu”, Romanian Academy, Spl Independentei 202B, 060023 Bucharest, Romania. E-mail: fdumitra@yahoo.com

<sup>b</sup>“Petru Poni” Institute of Macromolecular Chemistry, Aleea Gr. Ghica Voda 41A, Iasi 700487, Romania

<sup>c</sup>Faculty of Pharmacy, Ovidius University Constanta, Str. Cpt. Av. Al. Serbanescu 6, Campus Corp C, Constanta 900470, Romania

† Electronic supplementary information (ESI) available. CCDC 1849326, 1849327 and 1849329. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0ra02368j




Scheme 1 The synthesis of the starting *N*-arylglycines **1a–c**.Scheme 2 The synthesis of nitrosoaminoacids **2a–c** and subsequent synthesis of the halogenated *N*-arylsydnonones **3–5**.

The  $^1\text{H}$  NMR spectra of the *N*-arylglycines **1a–c** confirmed their structure. The isopropyl moiety appears as a doublet at 1.23–1.28 ppm with  $J = 6.8$  Hz and a sextet at 2.96 ppm with the same value of the coupling constant. The aromatic region of the  $^1\text{H}$  NMR spectra of the compounds **1a–c** presents the expected signals with the characteristic multiplicity (see Experimental section). The nitrosation of *N*-arylglycines **1a–c** was made with  $\text{NaNO}_2$  in presence of hydrochloric acid according to Scheme 2. The nitroso derivatives **2a–c** were obtained as crystalline solids in up to 90% yield.

From a careful examination of the NMR spectra of the nitrosoderivatives **2a–c** we concluded that these compounds were obtained as mixtures of *E–Z* isomers which were unquestionably observed at low temperatures due to the fact that in normal conditions the reaction leads to the most stable isomer as will be discussed further. The *E–Z* isomerism appears in nitrogen containing compounds in which C–N (*i.e.* amides, oximes, *etc*) or N–N (*i.e.* nitroso) presents partial double bond character due to conjugation.<sup>39–44</sup> However the *E–Z* isomerism in the case of nitrosoacids like **2a–c** was less investigated. The activation parameters of the *E–Z* inter-conversion in the case of nitrosoamines were investigated by dynamic NMR techniques.<sup>45,46</sup>

Also the *E–Z* configuration was attributed on the rationale that the most voluminous substituent must be in *cis* position in respect to the oxygen atom in the nitroso group. The  $^1\text{H}$  NMR spectrum of the compound **2a** shows that the signals of the protons in the isopropyl moiety and the protons in methylene attached to the nitrogen atom appear as two distinctive sets

Fig. 1 The  $^1\text{H}$  NMR spectrum of **2a** showing the presence of both the *Z–E* isomers and the atropisomerism of the isomer *Z-2a* depicted by the signal multiplicities of the methyl and methylene protons.

with the integral ratio of 95 : 5 (Fig. 1). For each distinctive sets of signals the multiplicities are different: the methylene attached to the N atom appears as a singlet (for the 95% isomer) and as two doublets forming an AB system with  $J = 17.8$  Hz for the 5% isomer. The same is valid for the isopropyl moiety, Table 1 presenting the signals in the aliphatic region and their corresponding multiplicities. The presence of two conformers is observed for *Z-2a* (Fig. 1) due to the hindered rotation about the C–N bond induced by the bulky isopropyl group and the contribution of the nitroso moiety. The different chemical shifts of the analogous atoms in the two rotamers are slightly different due to the magnetic anisotropy of the nitroso group which is in a different spatial relation with the interacting hydrogen atoms.

The *Z–E* isomerism was also observed for compounds **2b** and **2c**. For **2b** the protons in the aromatic ring, present two sets of signals corresponding to the two stereoisomers (Table 1) while H-6' presents different chemical shifts also due to the spatial influence of the nitroso group.


The non-equivalence of the methyl protons of the isopropyl moiety suggests that *Z-2a* and *Z-2b* present axial isomerism which is induced by the hindered rotation about the C–N bond caused by the bulky isopropyl group. This is elegantly confirmed in the case of **2c**, in which by introducing the bromine atom in the *ortho* position of the aryl ring with respect to the nitroso group gives the two *E–Z* stereoisomers in 58 : 42 ratio observed by  $^1\text{H}$  NMR spectroscopy (Fig. 1S<sup>†</sup>). Both *Z-2c* and *E-2c* present the coexistence of two stable conformers in solution (Table 1). The NMR studies indicated that *Z-2c* transforms in *E-2c* in solution similar to **2a** and **2b**. Thus one can conclude that *E-2c* is the thermodynamically stable stereoisomer and *Z-2c* is obtained by the nitrosation reaction of **1c** to **2c** which goes under kinetic control. We were able to separate *E-2c* from the mixture and to characterize it separately by NMR (Fig. 2S<sup>†</sup>) spectroscopy (see ESI<sup>†</sup>) and by single crystal X-ray diffraction analysis.

The structure of the *N*-nitrosophenylglycines **2** was investigated by X-ray single crystal diffraction of **2c** as representative compound. Suitable crystals of **2c** were grown by slow evaporation from acetonitrile. The X-ray diffraction analysis (Fig. 2)



**Table 1** The  $^1\text{H}$  NMR signals for the relevant protons in **2b** and **2c** showing the specific multiplicity characteristic to the *E-Z* isomers and the presence of the stable conformers of *Z-2b* and *E-2c* and *Z-2c* detectable in the NMR timescale at room temperature

Isomer	$\text{CH}_3$ , $\delta$ (ppm); $J$ (Hz)	$\text{CH}$ , $\delta$ (ppm); $J$ (Hz)	$\text{CH}_2$ , $\delta$ (ppm); $J$ (Hz)	H-6'	%
<i>E-2b</i>	1.22, d, 6.9	2.90, sep., 6.9	4.49, s	7.28, s	95
<i>Z-2b</i>	1.10, 1.16, 2d, 6.8	2.49, sep., 6.8	4.94, 5.53, 2d, 17.8	6.95, s	5
<i>E-2c</i>	1.18, 1.21, 2d, 6.9	3.38, sep., 6.9	3.95, 4.94, 2d, 16.8	—	58
<i>Z-2c</i>	1.10, 2d, 6.8	2.82, sep., 6.8	4.91, 5.78, 2d, 17.8	—	42



**Fig. 2** X-ray molecular structure of compound **2c** with atom labeling and thermal ellipsoids at 50% level.

confirms the structure of **2c** as being the *E* stereoisomer in solid state. The geometric parameters are listed in Table 2S (ESI).<sup>†</sup>


The crystal structure of **2c** can be characterized as the parallel packing of the discrete infinite ribbons running along a crystallographic axis (Fig. 3S<sup>†</sup>). The structure of one-dimensional ribbon-like supramolecular architecture is shown in Fig. 3 showing short  $\text{Br}\cdots\text{Br}$  contacts. The value of the intermolecular  $\text{Br}\cdots\text{Br}$  distance, 3.536(1) Å is under the sum of van der Waals radii (3.70 Å). Also the values of the angles  $\text{C}-\text{Br}\cdots\text{Br}$  are 113.0° and 173.9°, respectively.

The  $\text{Br}\cdots\text{Br}$  contacts are by definition included in the class of the halogen bonds of type II.<sup>47</sup>

The energy of the cyclic dimer made by the hydrogen bond in the carboxylic acid was calculated at HF/3-21 level as implemented in Crystal Explorer 17.<sup>48,49</sup> The calculated value of  $-73 \text{ kJ mol}^{-1}$  place the  $\text{O}-\text{H}\cdots\text{O}=\text{C}$  bond strength as usual for such kind of compounds.<sup>50</sup>

### Synthesis and characterization of the 3-arylsydnes 3-5

The new nitrosophenylglycines **2a-c** were used further in the synthesis of the *N*-arylsydnes **3a-c** (Scheme 2). The new




**Fig. 3** 1D supramolecular network in the crystal structure **2c**. H-atoms not involved in hydrogen bonding are omitted. H-bonds and  $\text{Br}\cdots\text{Br}$  contacts are shown in dashed-black lines.

sydnes were obtained in good yields (see ESI<sup>†</sup>). The sydnes **3a,b** were then halogenated in position 4 to give 4-bromosydnes **4a,b** and 4-iodosydnes **5a,b** by using iodine monochloride or molecular bromine. Unfortunately the halogenation in the case of **3c** did not give satisfactory results owing to prolonged reaction time or required higher temperatures which led to the decomposition of the reaction products.

The structure of the new compounds **3-5** (Table 2) was investigated and confirmed by NMR spectroscopy. The investigation of the NMR spectra showed that 1-arylsydnes **3c** and **4b** and **5a,b** present also stable rotamers induced by the hindered rotation between the phenyl and sydne ring given by the bulky isopropyl moiety and the voluminous halogen atom in position 4 of the sydne ring in the case of **4** and **5**. The diastereotopic isopropyl group has been used to probe the axial chirality which could be studied by NMR spectroscopy due to the magnetic non-equivalence of the methyl protons and carbon atoms caused by the hindered rotation around the C-N bond.

In the case of the sydnes **3a-c**, we could detect the presence of the two rotamers at room temperature, only in the case



**Fig. 4** The two methyl protons in the isopropyl group become anisochronous due to the hindered rotation about the C-N group. The  $^1\text{H}$  NMR signals of the two methyl protons in **3c** which coalesce at  $\sim 35^\circ\text{C}$ .

**Table 2** The structures and features of the new halogenated 3-arylsydnes **3-5**

No.	R	X	Yield (%)	Mp ( $^\circ\text{C}$ )
<b>3a</b>	H	H	87	68–69
<b>3b</b>	4-Br	H	72	100–101
<b>3c</b>	4,6-Dibromo	H	54	169–171
<b>4a</b>	H	Br	85	91–92
<b>4b</b>	4-Br	Br	82	142–144
<b>5a</b>	H	I	82	179–180
<b>5b</b>	4-Br	I	82	195–197






Fig. 5 X-ray molecular structure of compound **3c** with atom labeling and thermal ellipsoids at 50% level.

of **3c** which possess a Br atom attached to the other *ortho* position of the phenyl ring in respect to the sydnone and contributes by its volume to the steric hindrance between the phenyl and sydnone rings. Thus, in the  $^1\text{H}$  NMR spectrum of **3c** the methyl protons of the isopropyl appear as two doublets at room temperature (Fig. 4) while the  $^{13}\text{C}$  NMR spectrum presents two distinctive signals for the non-equivalent methyl carbon atoms.

In the case of 4-bromosydnone **4a,b** without a bromine in the position 6' of the benzene ring the  $^1\text{H}$  NMR spectra does not provide relevant data regarding the presence of axial chirality at room temperature but the  $^{13}\text{C}$  NMR spectrum present the methyl groups C atoms as a broad singlet showing that at room temperature the energy barrier for the free rotation about the C–N bond is reached. Comparing the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of compounds **3c** and **4a,b** one can conclude that the presence of a Br atom on the *ortho* position of the phenyl ring has a greater influence upon the free rotation than in the case it is attached to the 4 position of the sydnone ring as the presence of the two rotamers is clearly distinguished in solution. For the 4-iodosydnone **5a,b** the volume of iodine atom has an influence upon the signals of the methyl groups in the isopropyl moiety, the two methyl groups appearing as two distinct doublets in dilute solutions in  $^1\text{H}$  NMR. The  $^{13}\text{C}$  NMR spectra show also two distinct signals for the methyl groups. The free rotation energy barrier about the single bond must be therefore a little higher than in the analogous 4-brominated sydnone but still the free rotation has an energy sufficiently low to make to separate them in usual conditions.

The results of X-ray diffraction investigation for **3c** is depicted in Fig. 5, while bond distances and angles are summarized in Table 2S.† This compound exhibits a molecular crystal structure resulting from the packing of two-dimensional supramolecular double-layer in parallel orientation (as shown in Fig. 4S†). The self-assembling of two-dimensional layer occurs through the weak H-bonds where  $\text{C}_2\text{-H}$  group of the phenyl acts as donor towards carbonyl oxygen atom  $\text{O}_2$  of adjacent molecule as acceptor of proton (Fig. 4S†).

Each double-layer architecture is built-up from two 2D networks (Fig. 6), which is consolidated due to the  $\text{C-H}\cdots\text{O}$  hydrogen bonding and halogen $\cdots$ halogen interactions at  $3.6020(8)$  Å for  $\text{Br}\cdots\text{Br}'$  distance (Fig. 6). In the sydnone **3c** the intermolecular distance  $\text{Br}\cdots\text{Br}$   $3.6020(8)$  is also under the value of vdW and values of the angles  $\text{C-Br}\cdots\text{Br}$  of  $119.57^\circ$  and  $169.39^\circ$  respectively. The torsion angle between the plane of the phenyl ring and the plane of the sydnone ring has the value of  $86.5^\circ$ .





Fig. 6 2D supramolecular network in the crystal structure **3c**. H-atoms not-involved in hydrogen bonding are omitted. H-bonds and  $\text{Br}\cdots\text{Br}$  contacts are shown in dashed-black lines. H-bond parameters:  $\text{C}_2\text{-H}\cdots\text{O}_2$  [ $\text{C}_2\text{-H}$  0.93 Å,  $\text{H}\cdots\text{O}_2$  2.54 Å,  $\text{C}_2\cdots\text{O}_2(x, 1 - y, z)$  3.359(5) Å,  $\angle\text{C}_2\text{HO}_2$   $147.1^\circ$ ].



Scheme 3 The synthesis of the halogenated 1-arylpdrazoles **6a-g**.

Beside the halogen  $\text{Br}\cdots\text{Br}$  contacts in **3c** we observed that 4-iodosydnone presented interesting halogen bonding affinity in solution<sup>51</sup> in presence of different bases, and thus we envisaged that halogenated sydnone could provide ideal templates for studying the halogen bonding either in solution or solid state which will aim to investigate further.


### Synthesis and characterization of the 1-arylpdrazoles **6a-g**

The new halogenated 3-arylsydnone were employed in the final step in the synthesis of new halogenated 1-arylpdrazoles using the 1,3-dipolar cycloaddition reaction with activated acetylenic dipolarophiles. Thus, the new compounds **6a-g** were obtained starting from the sydnone **3-5** at reflux temperature in toluene or xylene as solvent (Scheme 3).

The mechanism of the  $[3 + 2]$  addition of the DMAD to sydnone was investigated<sup>28</sup> and generally accepted as going through a formation of a bicyclic intermediate **7** as presented in the Scheme 4 which leads to the final pyrazole compounds by elimination of one  $\text{CO}_2$  molecule and further aromatization (Path A). Literature data<sup>52,53</sup> suggest also another mechanism implying an acyclic intermediate of type **8** (Path B). In the case of the sydnone such intermediate was demonstrated to coexist







Scheme 4 Proposed mechanism pathways for the formation of the pyrazoles **6** by formal [3 + 2] cycloaddition of DMAD to sydnones.

Table 3 The new 1-arylpyrazoles **6a–g**

No.	R	X	Yield (%)	Mp (°C)
<b>6a</b>	H	H	87	62–63
<b>6b</b>	4-Br	H	94	139–140
<b>6c</b>	2,4-DiBr	H	67	113–115
<b>6d</b>	H	Br	87	92–93
<b>6e</b> <sup>52</sup>	H	I	82	156–157
<b>6f</b>	4-Br	Br	86	103–104
<b>6g</b>	4-Br	I	80	128–131

to a lesser extent with the bicyclic one, giving pyrazoles with another substitution pattern, a 1,3-dipole structure being suggested.<sup>27</sup>

Table 3 presents the new synthesized pyrazoles **6a–g** and their features.

Compounds **6a–g** were characterized by NMR spectroscopy and their structure was confirmed (Experimental section). The singlet in the range 8.03–8.06 belongs to H-5 proton in the pyrazole moiety while the protons in the phenyl group are in accordance with the substitution pattern. In the compounds **6a,b,d** the two methyl groups in the isopropyl moiety appear as doublets due to the coupling with the adjacent methine hydrogen. In compounds **6c** the presence of the bromine atom in the *ortho* position the phenyl ring is sufficient to increase the rotation barrier of the two rings about the single bond. This is reflected in the <sup>1</sup>H NMR spectrum by the magnetic non-equivalence of the two methyl groups which appear as two doublets at 1.12 and 1.19 ppm (Fig. 7). In the <sup>13</sup>C NMR spectra the methyl groups in the isopropyl moiety appear as a singlet for **6a,b,d** and for **6c** the spectrum shows two different signals highlighting the magnetic non-equivalence of the two protons in discussion. For the 5-bromopyrazoles **6d,f** the most important proof of the hindered rotation is the <sup>13</sup>C NMR which shows two signals for the methyl groups while the proton NMR being more sensible to dilution shows only one doublet. For the 5-iodopyrazoles **6e,g** the magnetic non-equivalence of the two methyl groups is clear in both <sup>1</sup>H and <sup>13</sup>C NMR spectra. The




Fig. 7 The <sup>1</sup>H NMR signals of the methyl groups in the isopropyl moiety for compound **6e**.




Fig. 8 X-ray molecular structure of compound **6b** with atom labeling and thermal ellipsoids at 50% level.

NMR data suggests that the most effective hindrance of the free rotation about Ar–N bond is when the halogen atom and the isopropyl group are both grafted on the same ring, the phenyl ring in particular.

The compound **6e** was studied by dynamic NMR and the resulted energy barrier of rotation was calculated at a coalescence temperature of 50 °C using the Gutowski relation. The energy was calculated to be 70.5 kJ mol<sup>-1</sup>, which is high enough to try the separation of the two enantiomers.

The structure of the highly substituted pyrazoles has been also confirmed by single crystal X-ray diffraction analysis. The molecular structure of the representative compound **6b** is shown in Fig. 8 and bond distances and angles in Table 1S.†

The analysis of the crystal packing shows the presence of two-dimensional supramolecular layers, which are formed by a system of intermolecular C–H⋯O hydrogen bonding. A view of this layer is depicted in Fig. 5S.† The crystal structure essentially results from the packing of these layers parallel to 011 plane, as shown in Fig. 6S.† The torsion angle between the plane of the phenyl ring and the plane of the pyrazole ring has the value of 75.57°.

We have investigated recently the propensity of halogen bonding in halogenated 1-arylpyrazoles and we found them as versatile structures for study of this interesting interaction.<sup>54</sup>

## Conclusions

In conclusion, new halogenated 3-(2-isopropylphenyl)sydnones and 1-(2-isopropylphenyl)pyrazoles were obtained from the corresponding *N*-nitrosoderivatives. The bulky halogen atoms on the phenyl or the five membered rings (sydnone and pyrazole) and the presence of the isopropyl on the *ortho* position of the phenyl ring induced a hindered rotation about the C–N bond, two stable rotamers being confirmed by NMR



spectroscopy in solution. The X-ray single crystal analysis confirmed the structure of the new compounds and highlighted their conformation in solid state. The X-ray diffraction confirmed the structure of the *E*-2c *N*-nitrosophenylglycine and showed similar Br...Br short contacts with sydnone **3c**. All the halogenated sydnones and pyrazoles are to be further investigated regarding their propensity for halogen bonding as the solution studies and X-ray diffraction analysis showed promising results.

## Experimental

### The synthesis of *N*-(2-isopropyl)phenylglycine (**1a**)

Mp 139–141 °C. Yield 46%. 30 mL (0.21 mol) of 2-isopropylaniline are mixed with 17 g (0.18 mol) of monochloroacetic acid in 200 mL water and 10 mL ethanol. The reaction mixture is kept under reflux for 3 h. The reaction mass is cooled with water and then stirred for 1 h on an ice bath. The formed precipitate is removed by filtration and then washed with water and with benzene after drying to remove any unreacted 2-isopropylaniline. Anal. for C<sub>11</sub>H<sub>15</sub>NO<sub>2</sub> (193.2): found: C 68.67; H 8.04; N 7.52. Calcd: C 68.37; H 7.82; N 7.25. <sup>1</sup>H NMR (CDCl<sub>3</sub>; δ, ppm; *J*, Hz): 1.28 (d, 6H, 6.8; Me); 2.96 (sep., 1H, 6.8; CHMe<sub>2</sub>); 4.03 (s, 2H, CH<sub>2</sub>); 6.15 (sl, 2H, COOH, NH); 6.54 (dd, 1H, 7.6; 1.5; H-6'); 6.83 (td, 7.6; 1.7; H-4'); 7.13 (td, 7.6; 1.5; H-5'); 7.19 (dd, 7.6; 1.7; H-3'). <sup>13</sup>C NMR (CDCl<sub>3</sub>; δ, ppm): 22.3 (Me); 27.3 (CHMe<sub>2</sub>); 46.0 (CH<sub>2</sub>); 110.8 (C-6'); 118.9 (C-4'); 125.3 (C-3'); 126.8 (C-5'); 133.0 (C-2'); 143.3 (C-1'); 176.1 (CO).

### The synthesis of *N*-phenylglycines **1b,c**

*N*-(2-Isopropyl)phenylglycine 3.9 g (20 mmol) are suspended in 20 mL glacial acetic acid. Over this solution is added by stirring 20 mmol Br<sub>2</sub> for **1b** or 40 mmol Br<sub>2</sub> for **1c** dissolved in 5 mL acetic acid. The reaction is kept under stirring for *cca.* 15–20 min and then the reaction mass is poured over cold water under continuous stirring. The formed precipitate is filtered and washed with water on the filter paper, and then the compound is dried.

***N*-(4-Bromo-2-isopropylphenyl)glycine (1b)**. White powder crystallized from ethyl acetate. Yield 94%, mp 191–193 °C. Anal. for C<sub>11</sub>H<sub>14</sub>BrNO<sub>2</sub> (272.14): found: C 48.87; H 5.47; Br 29.76; N 5.42. Calcd: C 48.55; H 5.19; Br 29.36; N 5.15. <sup>1</sup>H NMR (CDCl<sub>3</sub> + TFA; δ, ppm; *J*, Hz): 1.23 (d, 6H, 6.8; 2CH<sub>3</sub>); 3.25 (sep., 1H, 6.8; CHMe<sub>2</sub>); 3.91 (s, 2H, CH<sub>2</sub>); 7.33 (d, 1H, 8.6; H-6'); 7.51 (dd, 1H, 8.6; 2.2; H-5'); 7.64 (d, 1H, 2.2; H-3'); <sup>13</sup>C NMR (CDCl<sub>3</sub> + TFA; δ, ppm): 23.6 (CH<sub>3</sub>); 27.8 (CHMe<sub>2</sub>); 52.5 (CH<sub>2</sub>); 124.2 (C-6'); 124.9 (C-4'); 130.8 (C-2'); 131.3; 131.6 (C-3'; C-5'); 143.7 (C-1'); 168.9 (CO).

***N*-(4,6-Dibromo-2-isopropylphenyl)glycine (1c)**. White crystals were crystallized from cyclohexane; yield 76%; mp 103–105 °C (desc.). Anal. for C<sub>11</sub>H<sub>13</sub>Br<sub>2</sub>NO<sub>2</sub> (351.04): found: C 37.97; H 4.06; Br 45.90; N 4.31. Calcd: C 37.63; H 3.73; Br 45.52; N 3.99. <sup>1</sup>H NMR (CDCl<sub>3</sub>; δ, ppm; *J*, Hz): 1.23 (d, 6H; CH<sub>3</sub>); 3.25 (sep., 1H, 6.8; CHMe<sub>2</sub>); 3.91 (s, 2H, CH<sub>2</sub>); 7.29 (d, 1H, 2.2; H-3'); 7.53 (d, 1H, 2.2; H-5'); 7.70 (sl, 2H, NH, COOH). <sup>13</sup>C NMR (CDCl<sub>3</sub>; δ, ppm): 23.7 (2CH<sub>3</sub>); 28.7 (CHMe<sub>2</sub>); 50.3 (CH<sub>2</sub>); 116.7 (C-6'); 119.2 (C-4'); 129.0 (C-3'); 142.0 (C-1); 144.9 (C-1'); 176.7 (CO).

### Procedures for obtaining *N*-nitroso-*N*-phenylglycines

*N*-(2-Isopropylphenyl)glycine 20 mmol are dissolved in 40 mL solution of 5% NaOH and 21.5 mmol of NaNO<sub>2</sub> are added. Over this mixture 10 mL conc. HCl are added under vigorous stirring and cooling on an ice bath, until the pH will reach a value of 1.5–2. The stirring continues for another 15 min while the nitrosoderivative precipitates. The *N*-nitrosophenylglycine is filtered washed with water on the filter and let to dry in air.

***N*-Nitroso-*N*-(2-isopropylphenyl)glycine (2a)**. White crystals obtained from ethanol-benzene mixture; yield 94%; mp 104–106 °C (desc.). Anal.: C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub> (222.24): found: C 59.77; H 6.66; N 12.42. Calcd: C 59.45; H 6.35; N 12.21. <sup>1</sup>H NMR (CDCl<sub>3</sub>; δ, ppm; *J*, Hz): *E* (95%): 1.23 (d, 6H, 6.9; CH<sub>3</sub>); 2.94 (sep., 1H, 6.9; CHMe<sub>2</sub>); 4.52 (s, 2H, CH<sub>2</sub>); 7.31–7.44 (m, 2H, H-3; H-5); 7.49–7.53 (m, 2H, H-4; H-6); *Z* (5%): 1.12; 1.17 (2d, 6H, 6.8; CH<sub>3</sub>); 2.53 (sep., 1H, 6.8; CHMe<sub>2</sub>); 4.99; 5.55 (2d, 2H, 17.8; CH<sub>2</sub>); <sup>13</sup>C NMR (CDCl<sub>3</sub>; δ, ppm): *E* (95%): 24.0 (CH<sub>3</sub>); 28.2 (CHMe<sub>2</sub>); 50.1 (CH<sub>2</sub>); 126.9; 127.3; 130.3 (C-3', C-4', C-5', C-6'); 138.9 (C-1'); 145.4 (C-2'); 171.1 (CO). *Z* (5%): 23.7; 23.9 (CH<sub>3</sub>); 28.6 (CHMe<sub>2</sub>); 54.9 (CH<sub>2</sub>); (CO).

***N*-Nitroso-*N*-(4-bromo-2-isopropylphenyl)glycine (2b)**. The same procedure as for **2a** is employed. The compound precipitates as oil which is extracted twice with 15 mL CH<sub>2</sub>Cl<sub>2</sub>. This solution is dried over CaCl<sub>2</sub> and after the evaporation of CH<sub>2</sub>Cl<sub>2</sub> the amorphous mass is crystallized from ethyl acetate-benzene. Yield 89%; mp 121–123 °C (desc.). Anal. for C<sub>11</sub>H<sub>13</sub>BrN<sub>2</sub>O<sub>3</sub> (301.14): found: C 44.09; H 4.72; Br 26.94 N 9.59. Calcd: C 43.87; H 4.35; Br 26.53; N 9.30; <sup>1</sup>H NMR (CDCl<sub>3</sub>; δ, ppm; *J*, Hz): *E*: 1.22 (d, 6H, 6.9; CH<sub>3</sub>); 2.90 (sep., 1H, 6.9; CHMe<sub>2</sub>); 4.49 (s, 2H, CH<sub>2</sub>); 7.28 (d, 1H, 8.4; H-6'); 7.47 (dd, 1H, 8.4; 2.2; H-5'); 7.61 (d, 1H, 2.2; H-3'); 9.45 (sl, 2H, COOH); *Z*: 1.10; 1.16 (d, 6H, 6.9; CH<sub>3</sub>); 2.48 (sep., 1H, 6.9; CHMe<sub>2</sub>); 4.94; 5.53 (2d, 2H, 17.8; CH<sub>2</sub>); 6.95 (d, 1H, 8.4; H-6'); 7.37 (dd, 1H, 8.4; 2.2; H-5'); 7.50 (d, 1H, 2.2; H-3'); 9.45 (bs, 2H, COOH); <sup>13</sup>C NMR (CDCl<sub>3</sub>; δ, ppm): *E*: 23.6 (CH<sub>3</sub>); 28.4 (CH); 49.7 (CH<sub>2</sub>); 124.4 (C-4'); 128.5 (C-6'); 130.0; 130.6 (C-3'; C-5'); 137.8 (C-2'); 147.7 (C-1'); 170.9 (CO); *Z*: 52.3 (CH<sub>3</sub>); 34.4 (C-2'); 148.8 (C-1'); 173.4 (CO).

***N*-Nitroso-*N*-(4,6-dibromo-2-isopropylphenyl)glycine (2c)**. The same procedure as for **2a** white crystals were crystallized from cyclohexane; yield 78%; mp 170–172 °C (desc.); anal. for C<sub>11</sub>H<sub>12</sub>Br<sub>2</sub>N<sub>2</sub>O<sub>3</sub> (380.03): found: C 35.12; H 3.50; Br 42.44; N 7.69. Calcd: C 34.76; H 3.18; Br 42.05; N 7.37; <sup>1</sup>H NMR (CDCl<sub>3</sub>; δ, ppm; *J*, Hz): *E*: 1.18; 1.21 (2d, 6H, 6.7; CH<sub>3</sub>); 3.38 (sep., 1H, 6.7; CHMe<sub>2</sub>); 3.95; 4.94 (2d, 2H, 16.8; CH<sub>2</sub>); 7.59 (d, 1H, 2.1; H-3'); 7.74 (d, 1H, 2.1; H-5'); *Z*: 1.10 (d, 6H, 6.7; CH<sub>3</sub>); 2.82 (sep., 1H, 6.7; CHMe<sub>2</sub>); 4.91; 5.78 (2d, 2H, 17.8; CH<sub>2</sub>); 7.46 (d, 1H, 2.1; H-3'); 7.65 (dd, 1H, 2.1; 2.2; H-5'); <sup>13</sup>C NMR (CDCl<sub>3</sub>; δ, ppm): *E*: 23.1; 24.1 (CH<sub>3</sub>); 28.9 (CH); 51.2 (CH<sub>2</sub>); 122.2 (C-6'); 125.8 (C-4'); 130.4 (C-3'); 133.8 (C-5'); 136.3 (C-2'); 151.8 (C-1'); 171.2 (CO); *Z*: 23.4; 23.6 (CH<sub>3</sub>); 29.8 (CH); 54.2 (CH<sub>2</sub>); 130.1 (C-3'); 134.0 (C-5'); 173.4 (CO). <sup>13</sup>C NMR (CDCl<sub>3</sub> + TFA; δ, ppm): *E*: 23.4; 24.5 (CH<sub>3</sub>); 28.8 (CH); 49.8 (CH<sub>2</sub>); 122.8 (C-6'); 124.9 (C-4'); 130.1 (C-3'); 133.5 (C-5'); 136.9 (C-2'); 152.2 (C-1'); 171.2 (CO); *Z*: 23.8; 23.9 (CH<sub>3</sub>); 29.7 (CH); 53.6 (CH<sub>2</sub>); 129.7 (C-3'); 133.6 (C-5'); 173.6 (CO).



### General procedure for the synthesis of 3-(2-isopropylphenyl) sydnones 3–5

*N*-nitroso-*N*-(2-isopropylphenyl)glycine 20 mmol was dissolved in 30 mL acetic anhydride. On this solution is added 1 mL of dried pyridine. The reaction mixture is gently heated on a water bath at reduced pressure in order to evaporate the excess acetic anhydride and the acetic acid resulted from the reaction. The sydnone precipitates as oil which crystallizes upon cooling.

**3-(2-Isopropylphenyl)sydnone (3a).** White crystals were crystallized from ethanol; yield 87%; mp 68–69 °C. Anal. for  $C_{11}H_{12}N_2O_2$  (204.22): found: C 65.02; H 6.31; N 14.02. Calcd: C 64.69; H 5.92; N 13.71;  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.25 (d, 6H, 6.9;  $CH_3$ ); 2.84 (sep., 1H, 6.9;  $CHMe_2$ ); 6.49 (s, 1H, H-4); 7.37 (dd, 1H, 7.8; 1.6; H-3'); 7.39–7.45 (m, 1H, H-5'); 7.57 (dd, 1H, 7.8; 1.6; H-6'); 7.62–7.67 (m, 1H, H-4');  $^1H$  NMR ( $DMSO-d_6$ ,  $\delta$ , ppm, *J*, Hz): 1.20 (d, 6H, 6.9;  $CH_3$ ); 2.74 (sep., 1H, 6.9;  $CHMe_2$ ); 7.46–7.56 (m, 2H, H-3', H-5'); 7.55 (s, 1H, H-4); 7.63–7.75 (m, 2H, H-4', H-6');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 24.0 ( $CH_3$ ); 28.0 ( $CHMe_2$ ); 97.8 (C-4); 125.2 (C-3'); 127.0 (C-5'); 127.5 (C-6'); 132.7 (C-1'); 144.1 (C-2'); 168.8 (CO).

**3-(4-Bromo-2-isopropylphenyl)sydnone (3b).** White crystals were crystallized from ethanol; yield 72%; mp 100–101 °C. Anal. for  $C_{11}H_{11}BrN_2O_2$  (283.12): found: C 46.94; H 4.31; Br 28.60; N 10.22. Calcd: C 46.66; H 3.91; Br 28.22; N 9.89;  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.26 (d, 6H, 6.9; Me); 2.83 (sep., 1H, 6.9;  $CHMe$ ); 6.47 (s, 1H, H-4); 7.27 (d, 1H, 8.4; H-6'); 7.56 (dd, 1H, 8.4; 2.1; H-5'); 7.68 (d, 1H, 2.1; H-3');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 23.8 (Me); 28.2 ( $CHMe$ ); 97.6 (C-4); 126.8 (C-6'); 127.1 (C-4'); 130.4 (C-5'); 131.0 (C-3'); 131.6 (C-2'); 146.3 (C-1'); 168.4 (CO).  $^1H$  NMR ( $DMSO-d_6$ ,  $\delta$ , ppm, *J*, Hz): 1.19 (d, 6H, 6.8; Me); 2.71 (sep., 1H, 6.8;  $CHMe$ ); 7.53 (s, 1H, H-4); 7.64 (d, 1H, 8.4; H-6'); 7.71 (dd, 1H, 8.4; 2.1; H-5'); 7.89 (d, 1H, 2.1; H-3').  $^{13}C$  NMR ( $DMSO-d_6$ ,  $\delta$ , ppm): 23.3 (Me); 28.2 ( $CHMe$ ); 99.3 (C-4); 126.2 (C-6'); 128.1 (C-4'); 130.3, 130.4 (C-3', C-5'); 131.7 (C-2'); 146.2 (C-1'); 168.2 (CO).

**3-(4,6-Dibromo-2-isopropylphenyl)sydnone (3c).** White crystals were crystallized from ethanol; yield 54%; mp 169–171 °C. Anal. for  $C_{11}H_{10}Br_2N_2O_2$  (362.10): found: C 36.77; H 3.04; Br 44.46; N 8.09. Calcd: C 36.49; H 2.78; Br 44.14; N 7.74;  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.24; 1.25 (2d, 6H, 6.9; 2 $CH_3$ ); 2.63 (sep., 1H, 6.9;  $CHMe_2$ ); 6.47 (s, 1H, H-4); 7.63 (d, 1H, 2.0; H-3'); 7.80 (d, 1H, 2.0; H-5');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 23.6; 24.2 (2 $CH_3$ ); 29.4 ( $CHMe_2$ ); 98.1 (C-4); 120.3 (C-6'); 127.3 (C-4'); 129.7 (C-3'); 130.9 (C-1'); 133.8 (C-5'); 148.9 (C-1'); 168.5 (CO).

### General procedure for obtaining 4-brom-3-(2-isopropylphenyl) sydnones (4a,b)

3-(2-Isopropylphenyl)sydnone 10 mmol and 12 mmol sodium acetate anhydrous are dissolved in 15 mL glacial acetic acid. Over the reaction mixture are added under stirring and on an ice bath 11 mmol  $Br_2$  dissolved in 15 mL glacial acetic acid. The stirring is kept 10–15 minutes at room temperature and then the reaction mixture is poured over 150 mL of cold water. The formed precipitate is removed by filtration and washed with water on the filter paper.

**4-Bromo-3-(2-isopropylphenyl)sydnone (4a).** White crystals were crystallized from isopropanol; yield 85%; mp 91–92 °C.

Anal. for  $C_{11}H_{11}BrN_2O_2$  (283.12): found: C 46.95; H 4.22; Br 28.61; N 10.9; calcd: C 46.66; H 3.91; Br 28.22; N 9.89.  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.25 (d, 6H, 6.8; Me); 2.64 (sep., 1H, 6.8;  $CHMe_2$ ); 7.29 (dd, 1H, 7.9; 1.5; H-3'); 7.42–7.49 (m, 1H, H-5'); 7.59 (dd, 1H, 7.9; 1.5; H-6'); 7.65–7.71 (m, 1H, H-4');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 23.3 (bs, Me); 28.4 ( $CHMe_2$ ); 86.1 (C-4); 126.1; 127.3; 127.7 (C-3', C-5', C-6'); 131.6 (C-1'); 145.0 (C-2'); 165.5 (CO).

**4-Bromo-3-(4-bromo-2-isopropylphenyl)sydnone (4b).** White crystals were crystallized from ethanol; yield 82%. mp 142–144 °C. Anal. for  $C_{11}H_{10}Br_2N_2O_2$  (362.10): found: C 36.77; H 3.02; Br 44.53; N 8.02. Calcd: C 36.49; H 2.78; Br 44.14; N 7.74;  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.24 (d, 6H, 6.8; Me); 2.61 (sep., 1H, 6.8;  $CHMe$ ); 7.19 (d, 1H, 8.5; H-6'); 7.59 (dd, 1H, 8.5; 2.2; H-5'); 7.71 (d, 1H, 2.2; H-3');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 23.6 (sl, Me); 28.5 ( $CHMe$ ); 86.1 (C-4); 127.6 (C-6'); 127.7 (C-4'); 130.4 (C-3'); 130.7 (C-5'); 131.1 (C-2'); 147.1 (C-1'); 165.1 (CO).

**4-Iodo-3-(2-isopropylphenyl)sydnone (5a).** 3-(2-Isopropylphenyl)sydnone 10 mmol and 15 mmol anhydrous sodium acetate are dissolved in 15 mL acid acetic glacial. A solution of 12 mmol ICl in 5 mL acetic acid glacial is added under stirring and then the reaction mixture is stirred for 10 min at room temperature and another 1 h at 50–60 °C. After this, the reaction mixture is poured over 150 mL of cold water. The precipitated 4-iodosydnone is filtered and washed with water triturated with ethylic ether and crystalized from ethanol as white crystals. Yield 82%; mp 179–180 °C. Anal. for  $C_{11}H_{11}IN_2O_2$  (330.12): found: C 40.38; H 3.67; I 38.83; N 8.79. Calcd: C 40.02; H 3.35; I 38.44; N 8.48;  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.21; 1.22 (2d, 6H, Me); 2.55 (sep., 1H, 6.8;  $CHMe_2$ ); 7.23 (dd, 1H, 8.0; 1.5; H-3'); 7.39–7.45 (m, 1H, H-5'); 7.56 (dd, 1H, 8.0; 1.5; H-6'); 7.62–7.68 (m, 1H, H-4');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 22.7; 24.3 (2s, Me); 53.5 (C-4); 126.2; 127.6; 127.7 (C-3', C-5', C-6'); 132.9 (C-4'); 133.2 (C-1'); 144.8 (C-2'); 168.6 (CO).

**4-Iodo-3-(4-bromo-2-isopropylphenyl)sydnone (5b).** White crystals were crystallized from isopropanol; yield 82%; mp 195–197 °C. Anal. for  $C_{11}H_{10}BrIN_2O_2$  (409.02): N 7.04. Calcd: N 6.85;  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.24 (bd 6H, 6.9; Me); 2.56 (sep., 1H, 6.9;  $CHMe_2$ ); 7.15 (d, 1H, 8.4; H-6'); 7.59 (dd, 1H, 8.4; 2.1; H-5'); 7.70 (d, 1H, 2.1; H-3');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 22.7; 24.4 (2s, Me); 28.5 ( $CHMe_2$ ); 53.1 (C-4); 127.5 (C-4'); 127.7 (C-6'); 130.6 (C-3'); 131.1 (C-5'); 131.9 (C-2'); 146.9 (C-1'); 168.3 (CO).

### General procedure for the synthesis of the 1-arylpyrazoles 6

**Dimethyl 1-(2-isopropylphenyl)pyrazole-3,4-dicarboxylate (6a).** 10 mmol sydnone 4a and 12 mmol DMAD are heated under reflux in 20 mL toluene for 8 h. The solvent is evaporated and the resulted oil is eluted on an  $Al_2O_3$  column using  $CH_2Cl_2$  as solvent. The pyrazole 6a is crystallized from methanol as white crystals. Yield 87%; mp 62–63 °C; anal. for  $C_{16}H_{18}N_2O_4$  (302.3): found: C 63.87; H 6.33; N 9.55. Calcd: C 63.56; H 6.00; N 9.27.  $^1H$  NMR ( $CDCl_3$ ,  $\delta$ , ppm, *J*, Hz): 1.18 (d, 6H, 6.8;  $CH_3$ ); 2.80 (sep., 1H, 6.8;  $CHMe_2$ ); 3.89; 3.98 (2s, 6H,  $OCH_3$ ); 7.6–7.30 (m, 2H, H-3'; H-5'); 7.44–7.49 (m, 2H, H-4'; H-6');  $^{13}C$  NMR ( $CDCl_3$ ,  $\delta$ , ppm): 23.7 ( $CH_3$ ); 27.8 ( $CHMe_2$ ); 51.9; 52.5 ( $OCH_3$ ); 115.4 (C-4); 126.4; 126.7; 126.8 (C-3'; C-4'; C-5'); 130.3 (C-6'); 136.0 (C-5); 137.3 (C-1'); 143.9 (C-3); 144.8 (C-2'); 162.0 (2CO).





## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- C. Ollis and A. Ramsden, Meso-ionic Compounds, *Adv. Heterocycl. Chem.*, 1976, **19**, 1.
- F. Dumitrascu, M. R. Caira, B. Draghici, M. T. Caproiu and D. G. Dumitrescu, A novel approach for the synthesis of highly fluorescent pyrrolo[1,2-*b*]pyridazines, *Synlett*, 2008, 813–816.
- K. Sugimoto, Y. Miyakawa and H. Tokuyama, Total synthesis of (–)-rhazinilam using 1,3-dipolar cycloaddition of optically active münchnone intermediate, *Tetrahedron*, 2015, **71**, 3619–3624.
- Y. Fang, R. C. Larock and F. Shi, Aryne Cycloaddition with Stable Münchnones: Synthesis of 9,10-Dihydro-9,10-epiminoanthracenes and Isoindoles, *Asian J. Org. Chem.*, 2014, **3**, 55–57.
- C. M. Torres, J. S. Quesnel, D. B. Bijou and A. Arnsteden, From Aryl Iodides to 1,3-Dipoles: Design and Mechanism of a Palladium Catalyzed Multicomponent Synthesis of Pyrroles, *J. Am. Chem. Soc.*, 2016, **138**, 7315–7324.
- F. Bellina and R. Rossi, Synthesis and biological activity of pyrrole, pyrroline and pyrrolidine derivatives with two aryl groups on adjacent positions, *Tetrahedron*, 2006, **62**, 7213–7256.
- A. Ansari, A. Ali, M. Asif and S. Shamsuzzaman, Review: biologically active pyrazole derivatives, *New J. Chem.*, 2017, **41**, 16–41.
- S. Fustero, M. Sanchez-Rosello, P. Barrio and A. Simon-Fuentes, From 2000 to Mid-2010: A Fruitful Decade for the Synthesis of Pyrazoles, *Chem. Rev.*, 2011, **111**, 6984–7034.
- D. Vuluga, J. Legros, B. Crousse and D. Bonnet-Delpon, Synthesis of pyrazoles through catalyst-free cycloaddition of diazo compounds to alkynes, *Green Chem.*, 2009, **11**, 156–159.
- Z.-X. Wang and H.-L. Qin, Solventless syntheses of pyrazole derivatives, *Green Chem.*, 2004, **6**, 90–92.
- J. Jansa, R. Schmidt, A. D. Mamuye, L. Castoldi, A. Roller, V. Pace and W. Holzer, Synthesis of tetrasubstituted pyrazoles containing pyridinyl substituents, *Beilstein J. Org. Chem.*, 2017, **13**, 895–902.
- A. M. Abdulkader, M. Taher and N. I. N. Yusoff, Mesoionic sydnone: A review in their chemical and biological properties, *Int. J. Pharm. Pharmaceut. Sci.*, 2017, **9**, 1–9.
- F. Albota, M. R. Caira, C. Draghici, F. Dumitrascu and D. E. Dumitrescu, Sydnone C-4 heteroarylation with an indolizine ring via Chichibabin indolizine synthesis, *Beilstein J. Org. Chem.*, 2016, **12**, 2503–2510.
- F. Albota, C. Draghici, M. R. Caira and F. Dumitrascu, 1,3-Dipolar cycloaddition between acetylenic dipolarophiles and sydnone-N-ylides as bis(1,3-dipoles), *Tetrahedron*, 2015, **71**, 9095–9100.
- N. Pétry, T. Vanderbeeken, A. Malher, Y. Bringer, P. Retailleau, X. Bantreil and F. Lamaty, Mechanosynthesis of sydnone-containing coordination complexes, *Chem. Commun.*, 2019, **55**, 9495–9498.
- F. Dumitrascu, C. Draghici, D. Dumitrescu, L. Tarko and D. Raileanu, Direct iodination of sydnones and their cycloadditions to form 5-iodopyrazoles, *Liebigs Ann./Recl.*, 1997, 2613–2616.
- F. Dumitrascu, C. I. Mitan, D. Dumitrescu, C. Draghici and M. T. Caproiu, Steric effects on the sydnones reactivity. New sydnones and pyrazoles, *Arkivoc*, 2002, 80–86.
- F. Dumitrascu, C. Draghici, D. Vuluga and M. T. Caproiu, New pyrazoles by 1,3-dipolar cycloaddition reactions between sydnones and activated alkynes, *Rev. Roum. Chim.*, 2006, **51**, 255–260.
- W.-J. Hung and H.-J. Tien, Dehalogenation and Halogenation of Sydnone Compounds with Duet Electrosynthesis, *J. Chin. Chem. Soc.*, 1993, **40**, 637–639.
- T. Delaunay, P. Genix, M. Es-Sayed, J.-P. Vors, N. Monteiro and G. Balme, A Modular Sydnone Cycloaddition/Suzuki-Miyaura Cross-Coupling Strategy to Unsymmetrical 3,5-Bis(hetero)aromatic Pyrazoles, *Org. Lett.*, 2010, **12**, 3328–3331.
- T. Delaunay, M. Es-Sayed, J.-P. Vors, N. Monteiro and G. Balme, Facile Access to 3,5-Dihalogenated Pyrazoles by Sydnone Cycloaddition and their Versatile Functionalization by Pd-Catalyzed Cross-Coupling Processes, *Eur. J. Org. Chem.*, 2011, 3837–3848.
- D. C. Brown and K. Turnbull, Improved Method for the Iodination of Sydnones, *Synth. Commun.*, 2013, **43**, 3233–3237.
- I. A. Cherepanov and S. K. Moiseev, Recent developments in the chemistry of sydnones and sydnone imines, *Adv. Heterocycl. Chem.*, 2020, **131**, 49–164.
- I. F. Nashashibi, J. M. Tumej, B. L. Owens and K. Turnbull, Chlorination of 3-Arylsydnones with Iodine Monochloride, *Org. Prep. Proced. Int.*, 2017, **49**, 59–63.
- E. Decuypere, S. Specklin, S. Gabillet, D. Audisio, H. Liu, L. Plougastel, S. Kolodych and F. Taran, Copper(I)-Catalyzed Cycloaddition of 4-Bromosydnones and Alkynes for the Regioselective Synthesis of 1,4,5-Trisubstituted Pyrazoles, *Org. Lett.*, 2015, **17**, 362–365.
- H. Liu, D. Audisio, L. Plougastel, E. Decuypere, D.-A. Buisson, O. Koniev, S. Kolodych, A. Wagner, M. Elhabiri, A. Krzyczmonik, S. Forsback, O. Solin, V. Gouverneur and F. Taran, Ultrafast Click Chemistry with Fluorosydnones, *Angew. Chem., Int. Ed.*, 2016, **55**, 12073–12077.
- R. S. Foster, H. Adams, H. Jakobi and J. P. Harrity, Synthesis of 4-Fluoromethylsydnones and their Participation in Alkyne Cycloaddition Reactions, *J. Org. Chem.*, 2013, **78**, 4049–4064.
- V. Hladikova, J. Vana and J. Hanusek, [3 + 2]-Cycloaddition reaction of sydnones with alkynes, *Beilstein J. Org. Chem.*, 2018, **14**, 1317–1348.
- G. Zech, G. Hessler, A. Evers, T. Weiss, P. Florian, M. Just, J. Czech, W. Czechtizky, J. Gortitzer, M. Kohlmann and M. Nazare, Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone, *J. Med. Chem.*, 2012, **55**, 8615–8629.





- 30 M. Ito, T. Tanaka, D. R. Cary, M. Iwatani-yoshihara, Y. Kamada, T. Kawamoto, S. Aparicio, A. Nakanishi and Y. Imaeda, Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors, *J. Med. Chem.*, 2017, **60**, 3335–3351.
- 31 S. Poon, D. J. St. Jeana, P. E. Harrington, C. Henley III, J. Davis, S. Morony, F. D. Lott, J. D. Reagan, J. Y.-L. Lu, Y. Yang and C. Fotsch, Discovery and Optimization of Substituted 1-(1-Phenyl-1H-pyrazol-3-yl)methanamines as Potent and Efficacious Type II Calcimimetics, *J. Med. Chem.*, 2009, **52**, 6535–6538.
- 32 S. Cascioferro, B. Maggio, D. Raffa, M. V. Raimondi, M. G. Cusimano, D. Schillaci, B. Manachini, F. Plescia and G. Daidone, Synthesis and biofilm formation reduction of pyrazole-4-carboxamide derivatives in some *Staphylococcus aureus* strains, *Eur. J. Med. Chem.*, 2016, **123**, 58–68.
- 33 J. H. Kim, G. Keum, H. Chung and G. Nam, Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment, *Eur. J. Med. Chem.*, 2016, **123**, 665–672.
- 34 S. R. LaPlante, L. D. Fader, K. R. Fandrick, O. Hucke, R. Kemper, S. P. F. Miller and P. J. Edwards, Assessing Atropisomer Axial Chirality in Drug Discovery and Development, *J. Med. Chem.*, 2011, **54**, 7005–7022.
- 35 J. Wencel-Delord, F. R. Panossian and F. Colobert, Recent advances and new concepts for the synthesis of axially stereoenriched biaryls, *Chem. Soc. Rev.*, 2015, **44**, 3418–3430.
- 36 K. A. Brameld, B. Kuhn, D. C. Reuter and M. Stahl, Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis, *J. Chem. Inf. Model.*, 2008, **48**, 1–24.
- 37 M. Z. Hernandez, S. M. T. Cavalcanti, D. R. M. Moreira, W. F. de Azevedo Jr. and A. C. Lima-Leite, Halogen atoms in the modern medicinal chemistry: hints for the drug design, *Curr. Drug Targets*, 2010, **11**, 303–314.
- 38 Y. Lu, Y. Wang and W. Zhu, Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design, *Phys. Chem. Chem. Phys.*, 2010, **12**, 4543–4551.
- 39 D. S. Bohle, Z. Chua, I. Perepichka and K. Rosadiuk, *E/Z* Oxime Isomerism in PhC(NO<sub>2</sub>)CN, *Chem.–Eur. J.*, 2013, **19**, 4223–4229.
- 40 G. Szalontai, P. Sandor, F. Bangerter and L. Kollar, <sup>1</sup>H and <sup>13</sup>C dynamic NMR study of the *E*, *Z* isomers of vinylogous diamides. Effect of conjugation and electrostatic and steric repulsion on the C(O)-N rotation barriers and low-temperature conformation, *Magn. Reson. Chem.*, 1989, **27**, 216–222.
- 41 A. B. Lopes, E. Miguez, A. E. Kummerle, V. M. Rumjanek, C. A. M. Fraga and E. J. Barreiro, Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of N-acylhydrazone Derivatives, *Molecules*, 2013, **18**, 11683–11704.
- 42 J. S. Laursen, J. Engel-Adreasen, P. Fristrup, P. Harris and C. A. Olsen, *Cis-Trans* Amide Bond Rotamers in β-Peptoids and Peptoids: Evaluation of Stereoelectronic Effects in Backbone and Side Chains, *J. Am. Chem. Soc.*, 2013, **135**, 2835–2844.
- 43 P. Subramaniam, C. Ramasubbu and S. Athiramu, Exploiting intramolecular hydrogen bonding for the highly (*Z*)-selective & metal free synthesis of amide substituted β-aminoenones, *Green Chem.*, 2017, **19**, 2541–2545.
- 44 S. Ianelli, G. Pelosi, G. Ponticelli, M. T. Cocco and V. J. Onnis, Crystal and molecular structure of acetamidrazone derivatives, *J. Chem. Crystallogr.*, 2001, **31**, 149–154.
- 45 M. Oki, *Applications of Dynamic NMR Spectroscopy to Organic Chemistry*, VCH, New York, 1985.
- 46 M. Oki, *The chemistry of Rotational isomers*, Springer, Berlin, 1993.
- 47 G. Cavallo, P. Metrangolo, R. Milani, T. Pilati, A. Priimagi, G. Resnati and G. Terraneo, The Halogen Bond, *Chem. Rev.*, 2016, **116**, 2478–2601.
- 48 M. J. Turner, S. P. Thomas, M. W. Shi, D. Jayatilaka and M. A. Spackman, Energy frameworks: insights into interaction anisotropy and the mechanical properties of molecular crystals, *Chem. Commun.*, 2015, **51**, 3735–3738.
- 49 M. J. Turner, J. J. McKinnon, S. K. Wolff, D. J. Grimwood, P. R. Spackman, D. Jayatilaka and M. A. Spackman, *CrystalExplorer17*, University of Western Australia, 2017.
- 50 A. Gavezzoti, Hydrogen bond strength and bond geometry in cyclic dimers of crystalline carboxylic acids, *Acta Crystallogr., Sect. B: Struct. Sci.*, 2008, **64**, 401–403.
- 51 C. Draghici, M. R. Caira, D. E. Dumitrescu and F. Dumitrascu, Halogen Bonds of 4-Iodosydnonones in Solution Deduced from <sup>13</sup>C-NMR Spectra, *Rev. Chem.*, 2018, **69**, 843–845.
- 52 G. Mloston, M. Celeda, R. Jasinski and H. Heimgartner, Experimental and computational studies on stepwise [3+2]-cycloadditions of diaryldiazomethanes with electron-deficient dimethyl (*E*)- and (*Z*)-2,3-dicyanobutenedioates, *Eur. J. Org. Chem.*, 2019, 422–431.
- 53 R. Jasinski, K. Kula, A. Kacka and B. Miroslaw, Unexpected course of reaction between (*E*)-2-aryl-1-cyano-1-nitroethenes and diazafluorene: why is there no 1,3-dipolar cycloaddition?, *Monatsh. Chem.*, 2017, **148**, 909–915.
- 54 M. M. Popa, I. C. Man, C. Draghici, S. Shova, M. R. Caira, F. Dumitrascu and D. Dumitrescu, Halogen bonding in 5-iodo-1-arylpiperazines investigated in the solid state and predicted by solution <sup>13</sup>C-NMR spectroscopy, *CrystEngComm*, 2019, **21**, 7085–7093.

